BridGene Biosciences, Inc. today announced that Wolf Ruprecht Wiedemeyer, Ph.D., biology director at BridGene Biosciences, will be presenting at the inaugural Hippo Pathway Targeted Drug Development Summit 2022, being held by Hanson Wade at the DoubleTree Suites by Hilton Hotel Boston - Cambridge on May 24-26, 2022.
| Dr. Wolf Ruprecht Wiedemeyer to present at two seminars, Discovery and Development of Novel Covalent TEAD Inhibitors; and Leveraging the Hippo Pathway for Therapeutics Intervention – Optimizing Translation, Animal Models & Safety SAN JOSE, Calif., May 19, 2022 /PRNewswire/ -- BridGene Biosciences, Inc. a biotechnology company using a unique chemoproteomic technology to discover and develop small molecule drugs for high value, traditionally undruggable targets, today announced that Wolf Ruprecht Wiedemeyer, Ph.D., biology director at BridGene Biosciences, will be presenting at the inaugural Hippo Pathway Targeted Drug Development Summit 2022, being held by Hanson Wade at the DoubleTree Suites by Hilton Hotel Boston - Cambridge on May 24-26, 2022. Dr. Wiedemeyer’s presentation during “Discovery and Development of Novel Covalent TEAD Inhibitors,” will feature the BridGene IMTAC screening platform, the successful identification of distinct TEAD ligands, and the development of novel covalent TEAD inhibitors. He will also participate in a panel discussion titled “Leveraging the Hippo Pathway for Therapeutics Intervention – Optimizing Translation, Animal Models & Safety.”
Details of the event are as follows:
About BridGene Biosciences Contact Dave Schemelia (media)
SOURCE BridGene Biosciences |
View original content to download multimedia:
